CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera appoints Pascal E. R. Girin as chairman of board of directors

Read more

Our innovative solutions

CarThera’s medical devices allow for the treatment of brain tumors in outpatient procedures as well as for improvement in the bioavailability of chemotherapeutics

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera appoints Pascal E. R. Girin as chairman of board of directors

Read more

SonoCloud®

High Intensity Contact Ultrasound interstitial medical device

An implant that increases the intracerebral penetration of oncology drugs (+400%) by transiently opening the blood-brain barrier (BBB) without increasing dose or subsequent toxicity. The minimally invasive and easy to use SonoCloud® device is also applicable to the treatment of neurodegenerative diseases (e.g. Alzheimer’s).

Read more

 

SonoProbe®

High Intensity Contact Ultrasound interstitial medical device

img2

The only medical device capable of performing biopsy, treatment, and resection of brain tumors in a single, image-guided outpatient procedure, even for complex tumor geometries

The SonoProbe can also be used for the treatment of tumors located in other organs such as the liver or lung

Read more

Home Page
  • unnamed-2
    unnamed-3

     
  • News CarThera

    25.06.2019
    June 2019: CarThera appoints Pascal E. R. Girin as chairman of board of directors

    Pascal Girin brings wealth of experience in medical device and life sciences industries to support CarThera’s future growth. Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others. As chairman of CarThera’s board of directors, he will bring invaluable insight to the company’s business strategy and future development.

    25.06.2019
    March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant

    Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions with escalating ultrasound pressure levels. GBM patients treated with optimal pressure levels and MRI-detected disrupted BBB (11 patients) showed a median progression-free survival (PFS) of 4.11 months and a median overall survival (OS) of 12.94 months. This compares to 2.73 months and 8.64 months respectively, for GBM patients without BBB disruption (8 patients).

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.